Rezolute (RZLT) Debt to Equity (2011 - 2021)
Rezolute recorded quarterly Debt to Equity of $0.06 in Q1 2021, up 261919.96% quarter-over-quarter from $0.0 in Q4 2017.
Rezolute's Debt to Equity history runs 8 years deep, the most recent figure standing at $0.06 for Q1 2021.
- In Q1 2021, Debt to Equity changed N/A year-over-year to $0.06; the TTM figure through Mar 2021 stood at $0.06 (changed N/A YoY), while the FY2017 annual figure was $0.0, down 94.94% from the prior year.
- Debt to Equity came in at $0.06 for Q1 2021 at Rezolute, up from $0.0 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.06 in Q1 2021 to a low of $0.0 in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.06 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 0.06 |
| Dec 31, 2017 | 0.00 |
| Sep 30, 2017 | 0.00 |
| Jun 30, 2017 | 0.00 |
| Mar 31, 2017 | 0.00 |
| Dec 31, 2016 | 0.00 |
| Sep 30, 2016 | 0.00 |
| Jun 30, 2016 | 0.00 |
| Mar 31, 2016 | 0.01 |
| Dec 31, 2015 | 0.00 |
| Sep 30, 2015 | 0.00 |
| Jun 30, 2015 | 0.00 |
| Dec 31, 2014 | 0.14 |
| Sep 30, 2014 | 0.08 |
| Jun 30, 2014 | 0.01 |
| Mar 31, 2014 | 0.33 |
| Dec 31, 2013 | -0.24 |
| Sep 30, 2013 | -0.20 |
| Jun 30, 2013 | -0.04 |
| Mar 31, 2013 | -0.15 |
| Dec 31, 2012 | -0.65 |
| Dec 31, 2011 | 0.00 |